Website: https://peoplereign.io
Type of Company: Software & application
Company Status: Active
Business: PeopleReign is an enterprise software company that provides a virtual agent for IT and HR Helpdesk.
Outcome:
Co-investors: Moxxie Ventures
RADNOR, Pa., March 10, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced positive topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials evaluating the efficacy and safety of lorundrostat for the treatment of uncontrolled hypertension (uHTN) or resistant hypertension (rHTN). Both trials successfully achieved statistical significance and were clinically meaningful in their pre-specified primary efficacy endpoints and demonstrated a favorable safety and tolerability profile.
VIENNA, Va., Feb. 13, 2025 /PRNewswire/ --Antithesis, the autonomous software testing company, today marks its first year anniversary since launching out of stealth with the announcement of new funding and the expansion of its customer base, employee count, and board.
What does it take to lead a company that’s reshaping the future of energy? Drew Torbin, President of Black Bear Energy, a Legence Company, combines a passion for clean technology with a deep commitment to culture and community. In this executive spotlight interview, Drew dives into the exciting trends driving renewable energy, the unique dynamics of living and working in Boulder, and how Black Bear’s people-first culture keeps the team thriving.
Keahi Pelkum Donahue, a senior at Nederland Middle Senior High School, recently was named one of the top 300 scholars in the Regeneron Science Talent Search.
Donahue entered his project, “Forecasting Solar Flares with Transformer Networks,” in the science and math competition for high school seniors. The 300 scholars were selected from nearly 2,500 entrants. Each scholar will be awarded $2,000 each, as well as $2,000 for their schools.
Boulder, CO – December 10th, 2024 – Ambrosia Biosciences Inc. (“Ambrosia”), today announced the successful second closing of its Series A financing. This closing was led by Merck, known as MSD outside the United States and Canada, with additional participation from existing investors BVF Partners and Boulder Ventures. This additional capital brings Ambrosia’s total Series A financing to $25MM.
